Eli Lilly's strong quarter undercut by CVS move to drop Zepbound coverage
By Bhanvi Satija and Patrick Wingrove
(Reuters) -Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity drug Zepbound from the list of medicines it covers for reimbursement dragged shares down over 5%.
CVS said its pharmacy benefit management unit, which is the largest in the U.S., would drop Zepbound coverage from July 1, but keep reimbursing for rival GLP-1 weight-loss drug Wegovy after negotiating a more favorable price from Danish drugmaker Novo Nordisk.
The success of Lilly's diabetes and weight-loss treatments has led the Indianapolis-based drugmaker to become the world's most valuable healthcare company, with a market value of more than $800 billion.
"The battle between Novo and Lilly is clearly adding meaningful price pressure" to the GLP-1 medicines, said Bernstein analyst Courtney Breen, adding that patients and doctors have shown preference toward Zepbound.
Lilly said lower prices for Zepbound trimmed revenue in the quarter, but that demand remained strong. Sales of the drug came in at $2.31 billion for the first quarter, compared to analysts' expectations of $2.33 billion, according to LSEG data.
In February, Lilly cut the price for vials of Zepbound by $50 or more and expanded the range of doses it sold online to address competition from compounding pharmacies and Novo. It now offers the two lowest doses of Zepbound for $349 and $499 for a month's supply.
Weekly U.S. prescriptions of Wegovy have plateaued since mid-February, according to IQVIA data provided by analysts, with Zepbound prescriptions overtaking Novo's obesity drug by more than 127,000 for the week ending April 18.
Lilly said it had captured about 53.3% of the U.S. market share.
"There's always the risk of a price competition when your competitor Novo Nordisk is frankly not doing enough with its pipeline. So they may try to get a bit too aggressive on pricing just to maintain market share," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares.
Sales of Lilly's diabetes drug Mounjaro, which has the same active ingredient as Zepbound, were $3.84 billion, exceeding analysts' estimates of $3.80 billion.
Lilly cut its full-year adjusted profit forecast to between $20.78 and $22.28 per share, from its previous view of $22.50 to $24.00 per share, citing deal charges.
The drugmaker said its forecast is based on "the existing tariff and trade environment," and did not quantify any impact from potential tariffs.
Lilly, like Novartis and Johnson & Johnson, has committed to increasing its U.S. manufacturing presence, pledging to spend at least $27 billion as the threat of tariffs from U.S. President Donald Trump looms over the sector.
On an adjusted basis, Lilly earned $3.34 per share for the quarter, topping analysts' estimates by 32 cents.
Total revenue for the period was $12.73 billion, above Wall Street expectations of $12.67 billion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
11 minutes ago
- Business Upturn
Minda Corporation forms joint venture with Toyodenso to manufacture advanced automotive switches in India
Minda Corporation has entered into a strategic joint venture with Japan-based Toyodenso to provide end-to-end solutions for the Indian automotive switch market. The partnership will cover design, development, manufacturing, and marketing of advanced automotive switches for two-wheelers, passenger vehicles, and other automotive segments. Minda Corporation will hold a 60% majority stake in the joint venture, while Toyodenso will hold the remaining 40%. The venture has already secured orders from Indian customers and plans to set up a greenfield manufacturing facility in Noida, Uttar Pradesh. Operations at the plant are expected to begin in the second half of FY 2026–27. This collaboration aligns with Minda Corporation's strategy to localize new technologies and expand its synergistic product portfolio. Toyodenso will contribute cutting-edge engineering and technology, while Minda Corporation will leverage its strength in localized manufacturing and supply chain management. The partnership is poised to meet the growing demand for technologically advanced switches in the Indian automotive sector. Ashok Minda, Chairman & Group CEO, Minda Corporation Limited, commented, 'We are very excited and privileged to partner with Toyodenso, a Global Japanese company with rich legacy of technological innovation. This partnership marks a pivotal milestone in our journey to drive smart mobility solutions while fostering indigenous manufacturing by integrating globally recognized technologies into India's automotive ecosystem.' Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
20 minutes ago
- Yahoo
The cheap fat jabs sending big pharma into a frenzy
For many Americans who tuned in to watch the Super Bowl earlier this year, it was a surprise to find themselves fat-shamed during the ad break. 'Obesity is America's deadliest epidemic,' a voiceover said, as images of wobbling bellies, greasy burgers and giant apple pies flashed across TV screens. The Super Bowl's 127m-strong audience, who were tucking into an estimated 1.5bn chicken wings during the event, were warned that 'obesity leads to half a million deaths each year'. But Hims and Hers, the US online medicines company behind the ad, said people should not blame themselves. Instead, its advert claimed that 'the system' was keeping them 'sick and stuck', adding that 'there are medications that work, but they're priced for profits, not patients'. To the relief of viewers, Hims and Hers offered a 'life-changing' solution. Rather than paying hundreds of dollars each month for well-known, branded weight-loss jabs such as Wegovy, households could instead try Hims and Hers' cheaper, replica versions. 'This is the future of healthcare,' it argued. 'Join us in the fight for a healthier America.' However, for the likes of Danish obesity drug maker Novo Nordisk and US pharma rival Eli Lilly, which have claimed the rise of copycat jabs poses potential health risks, such claims have become a serious headache. Over the past few decades, both businesses have poured billions of dollars into obesity drug research – recently yielding blockbuster drugs Wegovy and Mounjaro. The rapid uptake of such drugs has prompted a surge in revenues for big pharma. But bosses are now increasingly worried that demand among American patients has been dented by a cluster of smaller, copycat companies. According to industry estimates from November, around a quarter of the 8m Americans on weight-loss drugs were taking knock-off replica versions. These medicines, known as 'compound' drugs, were priced at around $200 ($148) a month, compared to over $1,300 for some branded versions. Barclays analyst Emily Field says the boom in copycat weight-loss drugs has been a 'unique phenomenon' in the US, sparking an inevitable surge in legal claims that has drawn the attention of regulators. So-called compound drugs are essentially custom-made medicines created by pharmacies using the same active ingredients of patented drugs. Historically, compounding pharmacies create custom versions of medicines if they need to personalise them for patients. For example, if someone is unable to take a standard oral medicine in pill form, or is allergic to an ingredient in an existing medicine. Compounding pharmacies are also typically blocked from mass-producing their drugs. For weight-loss drugs, though, it has been a different story. After the US Food and Drug Administration (FDA) put semaglutide – marketed as the blockbuster obesity drug Wegovy – and tirzepatide – the same for Eli Lilly's Mounjaro – on the shortage list in 2022, compounders were allowed to ramp up production. 'It was almost like these companies found a loophole where they were allowed to do this on a mass scale,' says Field. The impact has been significant. At the start of this year, Novo Nordisk estimated that the copycat drugs accounted for around a third of the entire weight-loss market. That is despite warnings from the FDA about the health risks posed by compounded medicines, which do not have to be approved by the regulator. Beth, from Washington, says she was tempted by online ads for the compound medicines, having struggled with her weight since the pandemic. For her, the drugs helped her at a time when it seemed impossible to lose weight or stick to a diet. She dropped 30lbs over a few months of taking a compound weight-loss medicine. Others say they had little choice but to opt for compound versions, given that the branded medicines were too expensive and not covered by their health insurance. However, the situation is rapidly changing. Last month, the FDA banned mass production of copycat weight-loss treatments that use semaglutide, the ingredient in Novo Nordisk's Wegovy. It also removed tirzepatide from its shortage list last October. Novo Nordisk said the law has now made things clearer. 'Moving forward, any compounder that mass produces or sells knock-off drugs is breaking the law and compromising patient safety,' a spokesman said. Eli Lilly says the products 'pose potentially life-threatening health risks', adding: 'Patients shouldn't be exposed to risky, unapproved products when regulator-approved medicines are available.' Online medicines firms, also known as telehealth businesses, are now racing to find a way to continue getting cheaper, personalised replica drugs out to patients. Noom, a rival to Hims and Hers, has suggested it will still be able to sell compounded weight-loss drugs to patients under an exception set aside for 'personalised' medicines. Hims and Hers, meanwhile, has already struck a new deal with Novo to offer its branded obesity drug to patients. The US firm also said this month it was exploring expansion in the UK, after acquiring European rival Zava. Andrew Dudum, the Hims and Hers chief, suggested there could be 'expansive options in obesity that include that type of personalisation, or similar types', telling the Financial Times that it could sell replica obesity medicines in the UK and Europe. David Meinertz, the boss of Zava, agrees that there are opportunities for the business to grow outside of America. 'There's clearly the experience and expertise that Hims and Hers have built up in the US,' he says. 'But then we have things like the regulatory knowledge here in Zava, and this is where we combine our experiences and spearhead this effort.' Still, the situation in the UK is very different to the US. Here, the compounding pharmacy market is much smaller, with pharmacies able to prepare personalised medicines for patients if it is prescribed by a doctor. Elizabeth Philp, the co-founder of compounding pharmacy Roseway Labs, says there could be a role for more personalisation of medicines. 'The NHS will say wasted medication is one of their top issues – people who try medication, put it in their bathroom cupboard and never use it again because it didn't suit them,' she says. 'We can really help with that.' However, drug insiders argue it would be a 'very bad idea' if the UK started to think about bringing in cheaper compound medicines for weight loss. 'The real drugs are getting very cheap at volumes,' says one senior drug leader. 'Supply is not an issue.' It will be a message that Novo and Eli Lilly will seek to drum home as they seek to prevent smaller rivals from selling cheaper weight-loss medicines to patients. Still, the effects of this debate are already being felt by many in the US battling to lose weight. 'I cannot afford the full price at this time,' says Beth. 'I think it's awful that people are losing access to this medication due to finances or compounded meds going away. 'These drugs are literally life-changing.'
Yahoo
an hour ago
- Yahoo
Circus SE Appoints Former Helsing Top-Executive Sasha Borovik as General Counsel
Borovik, a Harvard Law graduate, brings 20+ years of legal leadership across AI, tech, and defense, including as Director of Legal Affairs at Microsoft and key legal architect behind defense AI leader Helsing's $5Bn scale-up. He brings deep expertise in global negotiations and IP strategy across commercial and defense sectors - working with customers such as NATO, the UN, and Ukrainian forces. Joins as Circus' first core defense executive to accelerate international growth and legal strategy following the CA-M launch as its first autonomous solution for the defense sector and the CA-1 serial production. MUNICH, June 11, 2025--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global leader in AI software and robotics for the food service industry, announces the appointment of Sasha Borovik as General Counsel effective June 11, 2025. A graduate of Harvard Law School with over two decades of global legal and commercial leadership, Borovik has negotiated complex technology, defense, and AI transactions on behalf of major corporations and institutions. His track record spans work with NATO-aligned governments, the UN, and AI leaders shaping next-generation defense infrastructure. At Helsing, Europe's leading defense AI company, Borovik played a pivotal role as General Counsel and Director of Compliance - not only building the legal function, but also leading the structuring and execution of multiple capital rounds totaling over $800 million to date. His legal leadership was instrumental in navigating dual-use technology regulation, defense contracting, and IP protection in one of Europe's most strategically important AI ventures. Prior to Helsing, Borovik served as Senior Director and Lead Counsel for EMEA at Akamai Technologies (Nasdaq: AKAM), and Director of Legal Affairs at Microsoft (Nasdaq: MSFT) as a head lawyer for the public sector, where he supported global expansion, strategic partnerships, and high-value commercial transactions across regulated markets. Borovik's appointment comes as Circus prepares for the launch of its CA-M defense product line, the world's first autonomous meal supply system designed for defense and critical infrastructure, and ramps up serial production of its core CA-1 system. As the company's first core defense executive, he will play a critical role in shaping commercial agreements, institutional partnerships, and regulatory strategy across dual-use domains. "Joining Circus is an opportunity to shape the strategic and legal backbone of a company that's redefining autonomy at scale," said Sasha Borovik. "With the CA-M and a growing international footprint, Circus is stepping into domains where legal rigor and regulatory foresight are not just an asset - they're mission-critical." "Sasha brings a rare combination of legal excellence, deal-making experience, and deep domain knowledge in defense and AI," said Nikolas Bullwinkel, CEO and Founder of Circus SE. "As we expand negotiations with multiple NATO-aligned forces and scale internationally, his leadership will be instrumental in building robust, long-term partnerships." Borovik holds law degrees from Harvard Law School and Charles University in Prague. He speaks seven languages and is admitted to the bar in both the European Union and the state of New York. About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply — on a mission to fuel humanity. Language: English Company: Circus SE Hongkongstrasse 6 20457 Hamburg Germany E-mail: ir@ Internet: ISIN: DE000A2YN355 WKN: A2YN35 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange View source version on Contacts Circus SEpress@
